Top 5 Clean Energy Companies To Own In Right Now

The recent budget proposal from the Obama administration is taking a lot of criticism for its big emphasis on clean energy technology development. While some may critique the method on how this will be funded, others fear the possibility of these clean energy investments failing,�the most recent and most widely publicized example being the bankrupt solar company Solyndra.�

Yet while we rake the muck of these failed�investments, many of us look over the fact that several industries and technologies were made possible from government funding.�Clearly, not every investment the government makes will be a great success, but�several�successful�businesses have developed in large part because of government assistance. There are examples across almost every sector of industry, but for now let's focus on developments in energy and see if a failure like Solyndra is an�aberration or just part of everyday business for the government.

Backing energy development: It's just what we do
The concept of having the government grant favorable treatment to the energy sector can be traced as far back as before the Civil War. At that time, the U.S. government's largest asset was land, and for many years it sold that land at below market value to encourage settlement and growth, which also gave a deep discount to the largest energy source at the time: timber. According to a research report by DBL Investors, the subsidies that were granted to the timber industry for energy purposes would have equated to about $25 billion per year in 2010 dollars.�

Top Long Term Stocks To Buy For 2015: Somaxon Pharmaceuticals Inc.(SOMX)

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment medical conditions in the central nervous system therapeutic area. Its product includes Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance. The company sells its products to wholesale distributors in the United States. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By CRWE]

  Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets.

Top 5 Clean Energy Companies To Own In Right Now: Burberry Group PLC (BRBY)

Burberry Group plc (Burberry) is a holding company. The Company designs and sources luxury apparel and accessories, selling through a diversified network of retail (including digital), wholesale and licensing channels worldwide. The Company�� Retail/wholesale channel is engaged in the sale of luxury goods through Burberry mainline stores, concessions, outlets and digital commerce, as well as Burberry franchisees, prestige department stores globally and multi-brand specialty accounts. The Company�� retail channel includes approximately 206 mainline stores, 214 concessions within department stores, digital commerce and 49 outlets. The Company�� wholesale channel includes sales to department stores, multi-brand specialty accounts, Travel Retail and franchisees who operates approximately 65 Burberry stores. Advisors' Opinion:

• [By Jonathan Morgan]

  Burberry (BRBY) added 1.8 percent to 1,488 pence. Revenue climbed 17 percent to 1.03 billion pounds, while adjusted pretax profit for the six months ended Sept. 30 rose to 174 million pounds from 173 million pounds a year earlier, the London-based trenchcoat maker said in a statement.

• [By Sofia Horta e Costa]

  Commodity producers slid as the release fueled concern about the slowdown in the world�� second-biggest economy. Burberry Group Plc (BRBY) gained 4.8 percent after the company�� spring-summer collection helped increase retail sales in its fiscal first quarter by more than analysts had estimated. Tryg A/S (TRYG) added 3.3 percent after posting better-than-forecast pretax profit as cost cuts offset increased weather-related claims.

• [By Sarah Jones]

  Burberry Group Plc (BRBY) climbed 1.4 percent to 1,299 pence. Goldman Sachs also added the U.K.�� largest luxury-goods maker to its conviction buy list. The brokerage said that Burberry�� fundamentals remain robust.

Top 5 Clean Energy Companies To Own In Right Now: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors' Opinion:

• [By Maxx Chatsko]

  Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.

• [By Keith Speights]

  Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."

Top 5 Clean Energy Companies To Own In Right Now: John Hancock Premium Dividend Fund (PDT)

John Hancock Patriot Premium Dividend Fund II (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is to provide high current income together with capital growth. The Fund invests in a diversified portfolio of dividend-paying preferred and common stocks. It invests at least 80% of its net assets in dividend-paying securities. The Fund will normally invest more than 65% of its total assets in securities of companies in the utilities industry. Preferred stocks and debt obligations in which the Fund invests are rated investment grade (at least BBB by Standard & Poor�� or Baa by Moody�� Investors Service) at the time of investment, or will be preferred stocks of issuers of investment-grade senior debt, or if not rated, will be of comparable quality as determined by the Fund�� investment advisor. The Fund will invest in common stocks of issuers, whose senior debt is rated investment grade, or in the case of issuers that have no rated senior debt outstanding, whose senior debt is considered by its advisor to be of comparable quality. Its portfolio includes common stocks, preferred securities and short-term investments.

In May 2007, the Fund completed the acquisition of John Hancock Patriot Preferred Dividend Fund. In June 2007, the Fund acquired Hancock John Patriot Global Dividend Fund and John Hancock Patriot Premium Div Fund I. On October 10, 2007, the Fund completed the acquisition of John Hancock Patriot Select Dividend Trust Fund.

The Fund invests in industries, such as multi-utilities, electric utilities, investment banking and brokerage, other diversified financial services, oil and gas exploration and production, gas utilities, consumer finance, life and health insurance, and integrated telecommunication services. John Hancock Patriot Premium Dividend Fund II�� investment advisor is John Hancock Advisers, LLC, a wholly owned subsidiary of John Hancock Financial Services, Inc., which is a subsidiary of Manulife Fina! ncial Corporation. The Fund�� sub-advisor is MFC Global Investment Management (U.S.), LLC.

Advisors' Opinion:

• [By Ari Charney]

  John Hancock Premium Dividend Fund (PDT) tends to allocate roughly 30% to 40% of the portfolio to equities and 60% to 70% to preferred stock, with the utilities and financial sectors as its main focus.